Premium
Single‐agent thalidomide induces response in T‐cell lymphoma
Author(s) -
Damaj G.,
Bouabdallah R.,
Vey N.,
Bilger K.,
Mohty M.,
Gastaut J. A.
Publication year - 2005
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/j.1600-0609.2004.00362.x
Subject(s) - thalidomide , lymphoma , cancer research , medicine , immunology , multiple myeloma
T‐cell lymphoma is an aggressive lymphoma that cannot be cured despite aggressive therapy, including autologous stem cell transplantation. Thalidomide is an immunomodulatory drug with numerous properties that has proven effective in relapsed multiple myeloma and, to a lesser extent, in other hematologic diseases. We report three cases of relapsed refractory T‐cell lymphoma treated with thalidomide with a good tumor response.